OncoMatch/Clinical Trials/NCT07189455

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Is NCT07189455 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including ZG006 and Topotecan for small-cell lung cancer.

Phase 3RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT07189455Data as of May 2026

Treatment: ZG006 · Topotecan — The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify